Track topics on Twitter Track topics that are important to you
SALT LAKE CITY, UT--(Marketwired - August 02, 2016) - Nu-Med Plus, Inc. (OTCBB: NUMD), a medical device development company, announced that the company will incorporate their newly developed proprietary nitric oxide generation and delivery system into the existing hospital delivery model prior to FDA 510k.
Jeff Robins, President and CEO of Nu-Med Plus, Inc. remarked, "It was a straight forward task to change the delivery system in our Hospital model over to our new proprietary Nitric Oxide generator. We believe that this will simplify the 510k submission and speed up the approval of this product." The new generation system takes advantage of room temperature operation and easier handling.
Nitric oxide is a medically essential gas that is presently used in Neonate Hypoxia therapy (inadequate oxygen level in newborns), pulmonary treatments and may have future applications for a variety of other diseases and complications, for example, wound healing and brain trauma that are currently being investigated.
About Nu-Med Plus, Inc.
Nu-Med Plus, Inc. is a medical device development company created to explore medical applications of newly developed technologies. The strategy is to focus on high growth potential markets where there is a clearly defined need recognized by the medical community that can be addressed by Nu-Med Plus and its technical expertise. Initial research and product development has been in the delivery of nitric oxide gas for therapeutic use. For more company information please visit www.nu-medplus.com.
Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management's current estimates, beliefs, intentions and expectations. They are not guarantees of future performance. The Company cautions that all forward looking statements are inherently uncertain and that actual performance may be affected by a number of material factors, many of which are beyond the Company's control. Such factors include, among other things: risks and uncertainties relating to the Company's ability to complete proposed private placement financing. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward looking information. Except as required under applicable securities legislation, the Company undertakes no obligation to publicly update or revise forward-looking information.Contact: Jeff RobinsPresident 801-746-3570NEXT ARTICLE
The role of medical devices in healthcare is essential. The diversity and innovativeness of this sector contribute significantly to enhance the quality and efficacy of healthcare. Covering a wide range of products, from simple bandages to the...
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...
Pulmonary relating to or associated with the lungs eg Asthma, chronic bronchitis, emphysema, COPD, Cystic Fibrosis, Influenza, Lung Cancer, Pneumonia, Pulmonary Arterial Hypertension, Sleep Disorders etc Follow and track Lung Cancer News ...